Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and drastically improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life that prevent infections and the diseases associated with chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, others are administered at the discretion of the prescribing physician and patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Despite notable competition, both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options.
QUESTIONS ANSWERED
What are the sizes of the populations eligible for key vaccination programs in the G7?
Who are the key decision-makers for vaccine purchasing and administration, and how does this role vary by geography?
What are the key drivers of brand preference in a given vaccine market?
For which pathogens is unmet need greatest for a new or improved vaccine? Which patient pools do experts indicate will be eligible for these vaccines?
How will the current vaccine pipeline fulfill areas of unmet need in the vaccine market?
How will key current and emerging vaccines perform commercially?
PRODUCT DESCRIPTION
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
HPV Vaccine-Eligible Population per 1,000 Adult Females in 2021 and 2041
HPV Vaccine-Eligible Population per 1,000 Adult Males in 2021 and 2041
HPV Vaccine-Eligible Population per 1,000 Adolescent Females in 2021 and 2041
HPV Vaccine-Eligible Population per 1,000 Adolescent Males in 2021 and 2041
HBV Vaccine-Eligible Population per 1,000 children in 2021 and 2041
HBV Vaccine-Eligible Population per 1,000 Adolescents in 2021 and 2041
HBV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
RSV Vaccine-Eligible Population per 1,000 Children in 2021 and 2041
Shingles Vaccine-Eligible Population per 1,000 People in 2021 and 2041
Influenza Vaccine-Eligible Population per 1,000 People in 2021 and 2041
Pneumococcal Vaccine-Eligible Population per 1,000 People in 2021 and 2041
Meningococcal B Vaccine-Eligible Population per 1,000 People in 2021 and 2041
Meningococcal ACWY Vaccine-Eligible Population per 1,000 People in 2021 and 2041
Epidemiology Data
Methods
HBV Vaccine-Eligible Population
HPV Vaccine-Eligible Population
Influenza Vaccine-Eligible Population
Pneumococcal Vaccine-Eligible Population
RSV Vaccine-Eligible Population
Shingles Vaccine-Eligible Population
Meningococcal ACWY Vaccine-Eligible Population
Meningococcal B Vaccine-Eligible Population
Reference Materials
Literature Review
Studies Included in the Analysis of Emerging Vaccines Eligible Population
Studies Excluded From the Analysis of Emerging Vaccines
Risk/Protective Factors
Risk / Protective Factors for Vaccine Eligibility
Bibliography
Abbreviations table
Glossary
Jagriti Prasad
Jagriti Prasad, M.P.H.,is an associate epidemiologist at Clarivate. Previously, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University (U.K.) and her B.D.S. from Manipal University (India).
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.